Kadmon Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: New York NY United States (2009)
Status: Acquired by Sanofi-Aventis (2021)

Organization Overview

First Clinical Trial
2009
NCT00086528
First Marketed Drug
2009
interferon alfacon-1 (Infergen)
First NDA Approval
2021
belumosudil (Rezurock)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Kadmon, a Sanofi Company | Kadmon Corporation, LLC | Kadmon Pharmaceuticals | Kadmon Pharmaceuticals LLC | KADMON PHARMS LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autoimmune Diseases (Phase 1)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Colorectal Neoplasms (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Fibrosis (Phase 2)

Glioblastoma (Phase 2)

Graft vs Host Disease (Phase 2)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 3)

Hyperlipidemias (Phase 2)

Hyperlipoproteinemias (Phase 2)

Hypertension (Phase 2)

Hypertriglyceridemia (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Kidney Diseases (Phase 2)

Liver Diseases (Phase 1)

Lung Neoplasms (Phase 2)

Meningeal Carcinomatosis (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Second Primary (Phase 2)

Polycystic Kidney, Autosomal Dominant (Phase 2)

Polycystic Kidney, Autosomal Recessive (Phase 1)

Polycystic Kidney Diseases (Phase 2)

Psoriasis (Phase 2)

Pulmonary Fibrosis (Phase 2)

Raynaud Disease (Phase 2)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Systemic (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 42
  • # of Trial APIs: 17